Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 46Colorectal Neoplasms 33Stomach Neoplasms 31Esophageal Squamous Cell Carcinoma 27Esophageal Neoplasms 14Rectal Neoplasms 12Cholangiocarcinoma 11Colonic Neoplasms 9Pancreatic Neoplasms 7Neoplasm Metastasis 6Sarcoma 5Carcinoma, Non-Small-Cell Lung 5Locally Advanced Rectal Cancer 4Biliary Tract Neoplasms 4Triple Negative Breast Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Melanoma 3Liver Neoplasms 3Carcinoma, Renal Cell 3Carcinoma 3Adenocarcinoma Of Esophagus 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms 2Mesothelioma 2Lung Neoplasms 2HER2-positive Gastric Cancer 2Endometrial Neoplasms 2Digestive System Neoplasms 2

Interventions

tislelizumab 1lenvatinib 1gemcitabine-oxaliplatin regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Potentially Resectable Locally Advanced Malignant Tumors of Biliary System × tislelizumab × Gastrointestinal × Clear all
NCT05036798 2022-09-07

Tislelizumab+Lenvatinib+Gemox Regiment for Potentially Resectable Locally Advanced Malignant Tumors of Biliary System.

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
30 enrolled
Gastrointestinal

Potentially Resectable Locally Advanced Malignant Tumors of Biliary System

Data powered by HemOnc (CC BY 4.0) Colophon âš¡